Clinical Research
Research studies
Clinical trials at OIC
Phase I-IV research in HIV treatment and prevention, hepatitis, vaccines, and emerging infectious diseases.
Now enrolling
2 studies are open to new participants
Merck-011 · Once-Monthly Oral PrEP Study (EXPRESSIVE)
A single tablet, once a month, for HIV prevention. This Phase 3 study evaluates MK-8527, an oral medication taken once monthly as HIV pre-exposure prophylaxis (PrEP) — an alternative to daily pills or injections. Route: Oral tablet, once monthly Length: Screening up to 45 days; treatment phase 30 months with 28-day follow-up Compensation: Stipend provided at each study visit You may pre-qualify if you are HIV-negative and at increased risk of HIV exposure. Contact our team for a confidential pre-screening. Protocol: MK8527-011 · Phase 3 · Sponsor: Merck
I’m interested →ViiV-222794 · QUATRO: Ultra Long-Acting HIV Maintenance
A Phase 3, randomized, multicenter, open-label, non-inferiority study evaluating cabotegravir ultra long-acting plus rilpivirine ultra long-acting (or cabotegravir long-acting plus rilpivirine long-acting) in adults and adolescents with HIV who are virologically suppressed on ART. Route: IM Length: 35 months Compensation: Stipend of $100 for scheduled/unscheduled visits, $200 for complicated visits (screening, baseline, Month 3, Month 7, and pregnancy LTFU), $25 for telephone contacts. Protocol: GSK222794 · Phase 3 · Sponsor: ViiV/GSK
I’m interested →Full directory